This segment focuses on the research, development, and clinical trials of gene therapy products for ocular diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The core technology involves the use of adeno-associated virus (AAV) vectors to deliver therapeutic genes directly to the retina via intravitreal injection. Research and development activities include preclinical studies, clinical trial design and execution (e.g., OPTIC, INFINITY, and ARTEMIS trials), and manufacturing process development. The primary product candidate is Ixo-vec (ADVM-022). Patient impact is focused on improving visual outcomes and reducing the treatment burden for patients with chronic retinal diseases. Market positioning is centered on providing a durable, single-administration therapy to replace frequent intravitreal injections. Future opportunities include expanding the application of gene therapy to other retinal diseases and exploring combination therapies. Regulatory and clinical aspects involve navigating FDA approval pathways and demonstrating long-term safety and efficacy. Partnerships and collaborations include agreements with various research institutions and pharmaceutical companies to advance the development and commercialization of gene therapy products.